Direct measurement of pancreatic enzymes after stimulation with secretin versus secretin plus cholecystokinin

What Was Tested

The paper reports a study of Secretin and Cholecystokinin (CCK) in the context of pancreatitis (after the acute phase), published as a randomized controlled trial.

The purpose of this study was to compare pancreatic enzyme levels after administration of secretin versus secretin plus cholecystokinin and to validate the timing of collection of duodenal fluid.

Why It Was Studied

Direct measurement of pancreatic enzymes after administration of pancreatic secretagogues is the gold standard in the assessment of exocrine pancreatic function.

Concomitant administration of intravenous cholecystokinin has been a subject of debate.

Who Took Part

PubMed indexes the participants as infants, young children, children and teenagers, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Secretin and who got the comparison, which limits bias.

As a double-blind Secretin study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Secretin could be set against what happens without it.

A prospective, randomized, double-blind study was conducted from September 1997 through September 1998.

Duodenal fluid was collected 5, 10, and 15 minutes later and placed in dry ice.

Samples were measured for the levels of trypsin, amylase, lipase, and chymotrypsin.

What Was Measured

Direct measurement of pancreatic enzymes after administration of pancreatic secretagogues is the gold standard in the assessment of exocrine pancreatic function.

PubMed files the paper under topics including Cholecystokinin, Duodenum, Endoscopy, Digestive System, Exocrine Pancreatic Insufficiency, Pancreas, Pancreatic Function Tests and Secretin.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Secretin and Cholecystokinin (CCK) in people with pancreatitis (after the acute phase).

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2000 (Journal of pediatric gastroenterology and nutrition), a journal based in United States.

More context: the Secretin compound page and the Cholecystokinin (CCK) compound page, Pancreatitis (after the acute phase) research.